DONQ52

DRUG2 trials

Sponsors

Chugai Pharmaceutical

Conditions

Celiac Disease

Phase 1

Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients

CompletedNCT05425446

Chugai PharmaceuticalCeliac Disease

Start: 2022-09-19End: 2025-01-17Updated: 2025-01-31

Phase 2

Study of DONQ52 in Active Celiac Disease

RecruitingNCT07239336

Chugai PharmaceuticalCeliac Disease

Start: 2025-12-16End: 2027-12-15Target: 92Updated: 2026-08-14